fluconazole has been researched along with Infant, Premature, Diseases in 77 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The authors conducted the first prospective, randomised controlled trial of nystatin compared with fluconazole for the prevention of fungal colonisation and invasive fungal infection in very low birth weight (VLBW) neonates." | 9.15 | Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. ( Akar, M; Aydemir, C; Dilmen, U; Dizdar, EA; Erdeve, O; Oguz, SS; Sarikabadayi, YU; Saygan, S, 2011) |
| "This observational pre-post cohort study was performed in preterm infants with a birth weight of < 1,000 g who were given prophylactic fluconazole starting on the first postnatal day at a dose of 3 mg/kg twice a week." | 7.80 | Efficacy of prophylactic fluconazole therapy in decreasing the incidence of Candida infections in extremely low birth weight preterm infants. ( Buyukkale, G; Cetinkaya, M; Ercan, TE; Kavuncuoglu, S; Mete, F; Saglam, OK, 2014) |
| "Although a fluconazole prophylaxis regimen for ELBW infants was effective in preventing invasive candidiasis, an increase in the incidence of conjugated hyperbilirubinemia was observed." | 7.73 | Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. ( Aghai, ZH; Amendolia, B; Kaki, S; Kemble, N; Longo, D; Mudduluru, M; Nakhla, TA; Saslow, JG; Stahl, GE; Sutsko, R, 2006) |
| " The authors previously reported an increased incidence of cholestasis with fluconazole prophylaxis in ELBW infants, which led to fluconazole prophylaxis being changed to a less frequent dosing (LFD) schedule of twice a week at their institution." | 6.76 | Twice-weekly fluconazole prophylaxis in premature infants: association with cholestasis. ( Aghai, ZH; Amendolia, B; Bhat, V; Fojas, M; Kemble, N; Pyon, K; Sannoh, S; Saslow, JG; Shah, S; Stahl, G, 2011) |
| " The authors conducted the first prospective, randomised controlled trial of nystatin compared with fluconazole for the prevention of fungal colonisation and invasive fungal infection in very low birth weight (VLBW) neonates." | 5.15 | Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. ( Akar, M; Aydemir, C; Dilmen, U; Dizdar, EA; Erdeve, O; Oguz, SS; Sarikabadayi, YU; Saygan, S, 2011) |
| "Prophylactic fluconazole reduces the incidence of colonization and invasive candida infection in neonates weighing less than 1500 g at birth." | 5.12 | A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. ( Arisio, R; Corona, G; Decembrino, L; Farina, D; Giovannozzi, C; Gomirato, G; Magnani, C; Manzoni, P; Maule, M; Merletti, F; Mosca, F; Mostert, M; Pedicino, R; Pugni, L; Stolfi, I; Stronati, M; Tridapalli, E; Vetrano, G, 2007) |
| " lusitaniae osteomyelitis in whom treatment was successful with 5-fluorocytosine and fluconazole." | 4.78 | Candida lusitaniae osteomyelitis in a premature infant. ( Della-Latta, P; Oleinik, EM; Rinaldi, MG; Saiman, L, 1993) |
| "This observational pre-post cohort study was performed in preterm infants with a birth weight of < 1,000 g who were given prophylactic fluconazole starting on the first postnatal day at a dose of 3 mg/kg twice a week." | 3.80 | Efficacy of prophylactic fluconazole therapy in decreasing the incidence of Candida infections in extremely low birth weight preterm infants. ( Buyukkale, G; Cetinkaya, M; Ercan, TE; Kavuncuoglu, S; Mete, F; Saglam, OK, 2014) |
| "Although a fluconazole prophylaxis regimen for ELBW infants was effective in preventing invasive candidiasis, an increase in the incidence of conjugated hyperbilirubinemia was observed." | 3.73 | Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. ( Aghai, ZH; Amendolia, B; Kaki, S; Kemble, N; Longo, D; Mudduluru, M; Nakhla, TA; Saslow, JG; Stahl, GE; Sutsko, R, 2006) |
| "We successfully characterized the PK of sildenafil and DMS in premature infants and applied the model to inform dosing for a follow-up, phase II study." | 2.90 | Population pharmacokinetics of sildenafil in extremely premature infants. ( Ambalavanan, N; Atz, A; Cohen-Wolkowiez, M; Gaedigk, R; Ge, S; Gonzalez, D; Hornik, CD; Hornik, CP; Laughon, MM; Martz, K; Mills, M; Mundakel, G; Poindexter, BB; Smith, PB; Sokol, GM; Stewart, D, 2019) |
| " The authors previously reported an increased incidence of cholestasis with fluconazole prophylaxis in ELBW infants, which led to fluconazole prophylaxis being changed to a less frequent dosing (LFD) schedule of twice a week at their institution." | 2.76 | Twice-weekly fluconazole prophylaxis in premature infants: association with cholestasis. ( Aghai, ZH; Amendolia, B; Bhat, V; Fojas, M; Kemble, N; Pyon, K; Sannoh, S; Saslow, JG; Shah, S; Stahl, G, 2011) |
| " Pharmacokinetic characteristics of fluconazole were determined after the first, third, and fifth doses." | 2.67 | Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. ( Hoppu, K; Pohjavuori, M; Saxén, H, 1993) |
| "Fungemia is a serious problem within neonatal intensive care units around the world." | 2.50 | Fungal prophylaxis in neonates: a review article. ( Bradshaw, WT; Lollis, TR, 2014) |
| "Fluconazole is a triazole antifungal agent that is widely used in the nursery." | 2.48 | Fluconazole use and safety in the nursery. ( Castagnola, E; Farina, D; Jacqz-Aigrain, E; Kaguelidou, F; Manzoni, P; Maragliano, R; Rizzollo, S; Stronati, M, 2012) |
| "Fluconazole prophylaxis lower the fungal colonization rate significantly (59." | 1.43 | Efficacy and safety of fluconazole prophylaxis in extremely low birth weight infants: multicenter pre-post cohort study. ( Choi, CW; Choi, EH; Choi, JH; Kim, BI; Kim, EK; Kim, HS; Lee, J; Shin, SH, 2016) |
| "Fluconazole prophylaxis was associated with a significant decrease in candidal BSI (odds ratio, 0." | 1.38 | Targeted fluconazole prophylaxis for high-risk very low birth weight infants. ( Klinger, G; Levy, I; Rolnitsky, A; Shalit, I; Sirota, L, 2012) |
| " The occurrence of LAMB-attributable renal toxicity was investigated; infants withdrawn from treatment for development of adverse effects or toxicity were identified." | 1.38 | Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates. ( Antonucci, R; Fanos, V; Farina, D; Franco, C; Galletto, P; Gallo, E; Manzoni, P; Rizzollo, S, 2012) |
| " However, further studies are warranted to better establish kinetics and appropriate dosing of these agents in premature and term infants, as well as their ability to improve late outcomes of ICI." | 1.38 | Correct choices for correct treatments: key issues in the management of Candida infections in preterm neonates. ( Castagnola, E; Farina, D; Jacqz-Aigrain, E; Manzoni, P; Maragliano, R; Rizzollo, S; Ruffinazzi, G; Stronati, M, 2012) |
| "Fluconazole prophylaxis has been used to control the problem." | 1.33 | Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. ( Koukila-Kähkölä, P; Luukkainen, P; Lyytikäinen, O; Pfaller, MA; Pujol, C; Richardson, M; Sarvikivi, E; Saxén, H; Soll, DR, 2005) |
| "Fluconazole was administered to 81% of ELBW infants, who received a median of 8 doses, and 41% of larger infants, who received a median of 5 doses." | 1.33 | Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. ( Brion, LP; Dave, VA; Herring, L; Marsh, J; Nafday, S; Reinersman, GT; Soghier, LM; Uko, S; Vega, M, 2006) |
| "Oral fluconazole is an alternative to parenteral amphotericin B in the treatment of premature infants, but proof of absorption and an extended treatment period according to prematurity might be warranted." | 1.31 | Candida arthritis in a premature infant treated successfully with oral fluconazole for six months. ( Weigl, JA, 2000) |
| "Oral fluconazole seems to be a safe and effective treatment for Candida albicans septicaemia even in premature infants." | 1.30 | Pharmacokinetics of oral fluconazole in premature infants. ( Hörnchen, H; Schefels, J; Skopnik, H; Wenzl, TG, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (16.88) | 18.2507 |
| 2000's | 27 (35.06) | 29.6817 |
| 2010's | 35 (45.45) | 24.3611 |
| 2020's | 2 (2.60) | 2.80 |
| Authors | Studies |
|---|---|
| Gonzalez, D | 1 |
| Laughon, MM | 1 |
| Smith, PB | 3 |
| Ge, S | 1 |
| Ambalavanan, N | 1 |
| Atz, A | 1 |
| Sokol, GM | 1 |
| Hornik, CD | 1 |
| Stewart, D | 1 |
| Mundakel, G | 1 |
| Poindexter, BB | 1 |
| Gaedigk, R | 1 |
| Mills, M | 1 |
| Cohen-Wolkowiez, M | 2 |
| Martz, K | 1 |
| Hornik, CP | 1 |
| Rundjan, L | 1 |
| Wahyuningsih, R | 1 |
| Oeswadi, CA | 1 |
| Marsogi, M | 1 |
| Purnamasari, A | 1 |
| Hanna Pharm, M | 1 |
| Mazkereth, R | 1 |
| Fortmann, I | 1 |
| Hartz, A | 1 |
| Paul, P | 1 |
| Pulzer, F | 1 |
| Müller, A | 1 |
| Böttger, R | 1 |
| Proquitté, H | 1 |
| Dawczynski, K | 1 |
| Simon, A | 1 |
| Rupp, J | 1 |
| Herting, E | 2 |
| Göpel, W | 1 |
| Härtel, C | 1 |
| Silva-Rios, J | 1 |
| Camargos, P | 1 |
| Correa, L | 1 |
| Romanelli, R | 1 |
| Luparia, M | 1 |
| Landi, F | 1 |
| Mesini, A | 1 |
| Militello, MA | 1 |
| Galletto, P | 4 |
| Farina, D | 10 |
| Castagnola, E | 3 |
| Manzoni, P | 11 |
| Austin, N | 4 |
| Darlow, BA | 3 |
| McGuire, W | 8 |
| Maede, Y | 1 |
| Ibara, S | 1 |
| Nagasaki, H | 1 |
| Inoue, T | 1 |
| Tokuhisa, T | 1 |
| Torikai, M | 1 |
| Ishihara, C | 1 |
| Matsui, T | 1 |
| Kodaira, Y | 1 |
| Chioukh, FZ | 1 |
| Ben Hmida, H | 1 |
| Ben Ameur, K | 1 |
| Toumi, A | 1 |
| Monastiri, K | 1 |
| Lollis, TR | 1 |
| Bradshaw, WT | 1 |
| Costa, S | 1 |
| Barone, G | 1 |
| Vento, G | 2 |
| Tirone, C | 2 |
| Perelli, S | 1 |
| Romagnoli, C | 2 |
| Cetinkaya, M | 1 |
| Ercan, TE | 1 |
| Saglam, OK | 1 |
| Buyukkale, G | 1 |
| Kavuncuoglu, S | 1 |
| Mete, F | 1 |
| Benjamin, DK | 2 |
| Hudak, ML | 1 |
| Duara, S | 1 |
| Randolph, DA | 1 |
| Bidegain, M | 1 |
| Mundakel, GT | 1 |
| Natarajan, G | 3 |
| Burchfield, DJ | 1 |
| White, RD | 1 |
| Shattuck, KE | 1 |
| Neu, N | 1 |
| Bendel, CM | 1 |
| Kim, MR | 1 |
| Finer, NN | 1 |
| Stewart, DL | 1 |
| Arrieta, AC | 1 |
| Wade, KC | 1 |
| Kaufman, DA | 3 |
| Prather, KO | 1 |
| Testoni, D | 1 |
| Berezny, KY | 1 |
| Islam, S | 1 |
| Singer, M | 1 |
| Kulhanjian, JA | 1 |
| Izquierdo, G | 1 |
| Pansieri, C | 1 |
| Pandolfini, C | 1 |
| Jacqz-Aigrain, E | 4 |
| van den Anker, J | 1 |
| Bonati, M | 1 |
| Kirpal, H | 1 |
| Gathwala, G | 1 |
| Chaudhary, U | 1 |
| Sharma, D | 1 |
| Cleminson, J | 2 |
| Lee, J | 1 |
| Kim, HS | 1 |
| Shin, SH | 1 |
| Choi, CW | 1 |
| Kim, EK | 1 |
| Choi, EH | 1 |
| Kim, BI | 1 |
| Choi, JH | 1 |
| Leonessa, M | 2 |
| Latino, MA | 3 |
| Arisio, R | 3 |
| Maule, M | 2 |
| Agriesti, G | 1 |
| Gastaldo, L | 1 |
| Gallo, E | 5 |
| Mostert, M | 5 |
| Kaufman, D | 2 |
| Vendettuoli, V | 1 |
| Posteraro, B | 1 |
| Clerihew, L | 4 |
| Aziz, M | 1 |
| Patel, AL | 1 |
| Losavio, J | 1 |
| Iyengar, A | 1 |
| Berven, M | 1 |
| Schloemer, N | 1 |
| Jakubowicz, A | 1 |
| Mathai, T | 1 |
| McAuley, JB | 1 |
| Aydemir, C | 1 |
| Oguz, SS | 1 |
| Dizdar, EA | 1 |
| Akar, M | 1 |
| Sarikabadayi, YU | 1 |
| Saygan, S | 1 |
| Erdeve, O | 1 |
| Dilmen, U | 1 |
| Bhat, V | 1 |
| Fojas, M | 1 |
| Saslow, JG | 2 |
| Shah, S | 1 |
| Sannoh, S | 1 |
| Amendolia, B | 2 |
| Pyon, K | 1 |
| Kemble, N | 2 |
| Stahl, G | 1 |
| Aghai, ZH | 2 |
| Tarnow-Mordi, W | 1 |
| Franco, C | 3 |
| Spera, AM | 1 |
| Rizzollo, S | 6 |
| Decembrino, L | 4 |
| Stronati, M | 6 |
| Lanari, M | 1 |
| Phute, SU | 1 |
| Bhakre, JB | 1 |
| Kristóf, K | 1 |
| Janik, L | 1 |
| Komka, K | 1 |
| Harmath, A | 1 |
| Hajdú, J | 1 |
| Nobilis, A | 1 |
| Rozgonyi, F | 1 |
| Nagy, K | 1 |
| Rigó, J | 1 |
| Szabó, D | 1 |
| Brissaud, O | 1 |
| Tandonnet, O | 1 |
| Guichoux, J | 1 |
| Martin, A | 1 |
| Pappas, A | 2 |
| Lulic-Botica, M | 2 |
| Rolnitsky, A | 1 |
| Levy, I | 1 |
| Sirota, L | 1 |
| Shalit, I | 1 |
| Klinger, G | 1 |
| Kaguelidou, F | 2 |
| Maragliano, R | 3 |
| Pugni, L | 2 |
| Stolfi, I | 2 |
| Vagnarelli, F | 1 |
| Corona, G | 2 |
| Tridapalli, E | 2 |
| Vetrano, G | 2 |
| Memo, L | 1 |
| Priolo, C | 1 |
| Giovannozzi, C | 2 |
| Pedicino, R | 2 |
| Barberi, I | 1 |
| Faldella, G | 1 |
| Mosca, F | 2 |
| Saia, OS | 1 |
| Bollani, L | 1 |
| Ruffinazzi, G | 2 |
| Tzialla, C | 1 |
| Antonucci, R | 1 |
| Fanos, V | 1 |
| Hameleers, SJ | 1 |
| Bergman, KA | 1 |
| Rulo, HF | 1 |
| Kuiper, H | 1 |
| Semmekrot, BA | 1 |
| Austin, NC | 1 |
| Darlow, B | 1 |
| Sarvikivi, E | 1 |
| Lyytikäinen, O | 1 |
| Soll, DR | 1 |
| Pujol, C | 1 |
| Pfaller, MA | 1 |
| Richardson, M | 1 |
| Koukila-Kähkölä, P | 1 |
| Luukkainen, P | 1 |
| Saxén, H | 2 |
| Rongkavilit, C | 1 |
| Bedard, M | 1 |
| Freydiere, AM | 1 |
| Piens, MA | 1 |
| Andre, JM | 1 |
| Putet, G | 1 |
| Picot, S | 1 |
| Gomirato, G | 2 |
| Fanaroff, AA | 1 |
| Uko, S | 1 |
| Soghier, LM | 1 |
| Vega, M | 1 |
| Marsh, J | 1 |
| Reinersman, GT | 1 |
| Herring, L | 1 |
| Dave, VA | 1 |
| Nafday, S | 1 |
| Brion, LP | 1 |
| Mudduluru, M | 1 |
| Nakhla, TA | 1 |
| Longo, D | 1 |
| Kaki, S | 1 |
| Sutsko, R | 1 |
| Stahl, GE | 1 |
| Khan, ZU | 1 |
| Al-Sweih, NA | 1 |
| Ahmad, S | 1 |
| Al-Kazemi, N | 1 |
| Khan, S | 1 |
| Joseph, L | 1 |
| Chandy, R | 1 |
| Magnani, C | 1 |
| Merletti, F | 1 |
| Sobel, JD | 1 |
| Revankar, SG | 1 |
| Vain, NE | 1 |
| Vazquez, LN | 1 |
| Procianoy, RS | 1 |
| Silveira, RC | 1 |
| Parikh, TB | 1 |
| Nanavati, RN | 1 |
| Patankar, CV | 1 |
| Rao, S | 1 |
| Bisure, K | 1 |
| Udani, RH | 1 |
| Mehta, P | 1 |
| Weitkamp, JH | 1 |
| Ozdas, A | 1 |
| LaFleur, B | 1 |
| Potts, AL | 1 |
| Kamitsuka, MD | 1 |
| Nugent, NA | 1 |
| Conrad, PD | 1 |
| Swanson, TN | 1 |
| Weintrub, PS | 1 |
| Chapman, A | 1 |
| Piecuch, R | 1 |
| Hoppu, K | 1 |
| Pohjavuori, M | 1 |
| Oleinik, EM | 1 |
| Della-Latta, P | 1 |
| Rinaldi, MG | 1 |
| Saiman, L | 1 |
| Gürses, N | 1 |
| Kalayci, AG | 1 |
| Melville, C | 1 |
| Kempley, S | 1 |
| Graham, J | 1 |
| Berry, CL | 1 |
| Merchant, RH | 1 |
| Sanghvi, KP | 1 |
| Sridhar, N | 1 |
| Sonigara, S | 1 |
| Mehta, KP | 1 |
| Joshi, NC | 1 |
| Wenzl, TG | 1 |
| Schefels, J | 1 |
| Hörnchen, H | 1 |
| Skopnik, H | 1 |
| Robinson, LG | 1 |
| Jain, L | 1 |
| Kourtis, AP | 1 |
| Weigl, JA | 1 |
| Boyle, R | 1 |
| Hazen, KC | 1 |
| Patrie, JT | 1 |
| Robinson, M | 1 |
| Donowitz, LG | 1 |
| Dani, C | 1 |
| Bertini, G | 1 |
| Pezzati, M | 1 |
| Casalaz, D | 1 |
| Harms, K | 1 |
| Schiffmann, JH | 1 |
| Speer, CP | 1 |
| Lee, BE | 1 |
| Feinberg, M | 1 |
| Abraham, JJ | 1 |
| Murthy, AR | 1 |
| Cruciani, M | 1 |
| Di Perri, G | 1 |
| Molesini, M | 1 |
| Vento, S | 1 |
| Concia, E | 1 |
| Bassetti, D | 1 |
| Wiest, DB | 1 |
| Fowler, SL | 1 |
| Garner, SS | 1 |
| Simons, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia[NCT04447989] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-05-27 | Recruiting | ||
| Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants: a Randomized Controlled Trial[NCT03390374] | Phase 4 | 95 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants < 750 Grams Birth[NCT00734539] | Phase 3 | 362 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Definite or probable (NCT00734539)
Timeframe: prior to hospital discharge, up to 15 ½ months
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 8 |
| Placebo | 19 |
(NCT00734539)
Timeframe: 36 weeks corrected gestational age
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 114 |
| Placebo | 93 |
"The primary endpoint for the study is death or candidiasis.~Death prior to study day 49.~Candidiasis prior to study day 49~Definite: isolation of Candida from normally sterile body fluid (blood, CSF, urine [obtained via sterile catheterization or suprapubic tap], peritoneal fluid).~Probable:~i. > 5 days of consecutive antifungal therapy~AND both:~ii. Thrombocytopenia <150,000/mm3 iii. Positive Candida culture from nonsterile site (ETS, bag urine)" (NCT00734539)
Timeframe: study day 49
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 31 |
| Placebo | 37 |
(NCT00734539)
Timeframe: prior to hospital discharge, up to 15 ½ months
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 16 |
| Placebo | 9 |
Grade 3 or 4 (NCT00734539)
Timeframe: prior to hospital discharge, up to 15 ½ months
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 33 |
| Placebo | 31 |
(NCT00734539)
Timeframe: prior to hospital discharge, up to 15 ½ months
| Intervention | days (Median) |
|---|---|
| Fluconazole | 113 |
| Placebo | 107 |
Bayley-III cognition composite score of less than 70, blindness, deafness, or cerebral palsy (NCT00734539)
Timeframe: 18-22 months corrected gestational age
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 27 |
| Placebo | 23 |
(NCT00734539)
Timeframe: prior to hospital discharge, up to 15 ½ months
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 46 |
| Placebo | 43 |
(NCT00734539)
Timeframe: prior to hospital discharge, up to 15 ½ months
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 10 |
| Placebo | 6 |
(NCT00734539)
Timeframe: prior to hospital discharge, up to 15 ½ months
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 109 |
| Placebo | 100 |
(NCT00734539)
Timeframe: prior to hospital discharge, up to 15 ½ months
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 29 |
| Placebo | 25 |
(NCT00734539)
Timeframe: prior to hospital discharge, up to 15 ½ months
| Intervention | participants (Number) |
|---|---|
| Fluconazole | 25 |
| Placebo | 23 |
15 reviews available for fluconazole and Infant, Premature, Diseases
| Article | Year |
|---|---|
Which Patient in the Neonatal Intensive Care Unit should Receive Antifungal Prophylaxis Therapy?
Topics: Antifungal Agents; Candidiasis, Invasive; Drug Resistance, Fungal; Fluconazole; Humans; Infant, Extr | 2021 |
Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Fluconazole; Humans; Infant, Newbo | 2013 |
Fungal prophylaxis in neonates: a review article.
Topics: Administration, Intravenous; Administration, Oral; Amphotericin B; Antifungal Agents; Aspergillosis; | 2014 |
Toxic epidermal necrolysis in a neonate receiving fluconazole.
Topics: Disease Progression; Fatal Outcome; Female; Fluconazole; Humans; Infant, Newborn; Infant, Premature; | 2014 |
Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants.
Topics: Antifungal Agents; Developmental Disabilities; Fluconazole; Humans; Infant, Newborn; Infant, Prematu | 2015 |
Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Fluconazole; Humans; Infant, Newbo | 2015 |
Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants.
Topics: Administration, Oral; Antifungal Agents; Candidiasis; Candidiasis, Chronic Mucocutaneous; Fluconazol | 2009 |
The effect of fluconazole prophylaxis in very low birthweight infants is overestimated by before-after studies.
Topics: Antifungal Agents; Fluconazole; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2010 |
Clinical use of lactoferrin in preterm neonates: an update.
Topics: Age of Onset; Animals; Bacterial Infections; Bacterial Translocation; Cattle; Fluconazole; Humans; I | 2010 |
Fluconazole use and safety in the nursery.
Topics: Antifungal Agents; Candida; Candidiasis, Invasive; Fluconazole; Humans; Infant; Infant, Newborn; Inf | 2012 |
"Getting to Zero": preventing invasive Candida infections and eliminating infection-related mortality and morbidity in extremely preterm infants.
Topics: Antifungal Agents; Candidiasis, Invasive; Fluconazole; Humans; Infant, Newborn; Infant, Premature, D | 2012 |
Antifungal therapy for newborn infants with invasive fungal infection.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Flucytosine; Humans; Infant, Newborn; Infant, Premat | 2012 |
Prophylactic oral antifungal agents to prevent systemic candida infection in preterm infants.
Topics: Administration, Oral; Antifungal Agents; Candidiasis; Candidiasis, Chronic Mucocutaneous; Fluconazol | 2004 |
Systemic antifungal drugs for invasive fungal infection in preterm infants.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Humans; Infant, Newborn; Infant, Premature; Infant, | 2004 |
Candida lusitaniae osteomyelitis in a premature infant.
Topics: Candidiasis; Diseases in Twins; Fluconazole; Flucytosine; Humans; Infant, Newborn; Infant, Premature | 1993 |
11 trials available for fluconazole and Infant, Premature, Diseases
| Article | Year |
|---|---|
Population pharmacokinetics of sildenafil in extremely premature infants.
Topics: Administration, Oral; Cohort Studies; Cytochrome P-450 CYP3A; Fluconazole; Gestational Age; Humans; | 2019 |
Oral nystatin prophylaxis to prevent systemic fungal infection in very low birth weight preterm infants: a randomized controlled trial.
Topics: Antifungal Agents; Fluconazole; Humans; Indonesia; Infant; Infant, Newborn; Infant, Premature; Infan | 2020 |
Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial.
Topics: Antifungal Agents; Candidiasis, Invasive; Female; Fluconazole; Humans; Infant Mortality; Infant, Low | 2014 |
Prophylactic fluconazole in very low birth weight infants admitted to neonatal intensive care unit: randomized controlled trial.
Topics: Antifungal Agents; Candidiasis; Female; Fluconazole; Humans; India; Infant, Newborn; Infant, Prematu | 2016 |
Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants.
Topics: Antifungal Agents; Birth Weight; Disease Progression; Drug Resistance, Fungal; Epidemiologic Methods | 2011 |
Twice-weekly fluconazole prophylaxis in premature infants: association with cholestasis.
Topics: Antifungal Agents; Candidiasis, Invasive; Cholestasis; Drug Administration Schedule; Female; Flucona | 2011 |
Clinical characteristics and response to prophylactic fluconazole of preterm VLBW neonates with baseline and acquired fungal colonisation in NICU: data from a multicentre RCT.
Topics: Antifungal Agents; Candida; Candidiasis, Invasive; Female; Fluconazole; Humans; Infant; Infant, Newb | 2012 |
A multicenter, randomized trial of prophylactic fluconazole in preterm neonates.
Topics: Antifungal Agents; Candida; Candidiasis; Cholestasis; Double-Blind Method; Female; Fluconazole; Huma | 2007 |
Fluconazole prophylaxis against fungal colonization and invasive fungal infection in very low birth weight infants.
Topics: Antifungal Agents; Candidiasis; Double-Blind Method; Fluconazole; Humans; Infant, Newborn; Infant, P | 2007 |
Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life.
Topics: Candidiasis; Female; Fluconazole; Half-Life; Humans; Infant, Low Birth Weight; Infant, Newborn; Infa | 1993 |
Fluconazole prophylaxis against fungal colonization and infection in preterm infants.
Topics: Antifungal Agents; Bacterial Infections; Candida; Candida albicans; Candidiasis; Colony Count, Micro | 2001 |
51 other studies available for fluconazole and Infant, Premature, Diseases
| Article | Year |
|---|---|
Antifungal Treatment and Outcome in Very Low Birth Weight Infants: A Population-based Observational Study of the German Neonatal Network.
Topics: Antifungal Agents; Candida; Candidiasis; Child, Preschool; Cohort Studies; Female; Fluconazole; Foll | 2018 |
Prophylactic regimens with fluconazole for candidiasis in neonates under 1.500g: A retrospective chart review of two cohorts.
Topics: Antifungal Agents; Candidiasis, Invasive; Chemoprevention; Female; Fluconazole; Humans; Incidence; I | 2019 |
Fungal Ecology in a Tertiary Neonatal Intensive Care Unit after 16 Years of Routine Fluconazole Prophylaxis: No Emergence of Native Fluconazole-Resistant Strains.
Topics: Antifungal Agents; Candida; Candidiasis; Colony Count, Microbial; Drug Resistance, Fungal; Female; F | 2019 |
Micafungin versus fluconazole for prophylaxis against fungal infections in premature infants.
Topics: Antifungal Agents; Echinocandins; Female; Fluconazole; Historically Controlled Study; Humans; Infant | 2013 |
[Saccharomyces cerevisiae fungemia in a premature neonate treated receiving probiotics].
Topics: Antifungal Agents; Apnea; Candidemia; Catheter-Related Infections; Diagnosis, Differential; Equipmen | 2013 |
Adrenocortical insufficiency is not a problem in preterm infants treated with antifungal prophylaxis with fluconazole.
Topics: Amphotericin B; Antifungal Agents; Antigens, Fungal; Apgar Score; Bronchoalveolar Lavage Fluid; Cand | 2014 |
Efficacy of prophylactic fluconazole therapy in decreasing the incidence of Candida infections in extremely low birth weight preterm infants.
Topics: Antifungal Agents; Birth Weight; Candidiasis, Invasive; Female; Fluconazole; Gestational Age; Humans | 2014 |
[Prophylaxis with fluconazole on invasive candidiasis and mortality in premature infants].
Topics: Antifungal Agents; Candidiasis, Invasive; Female; Fluconazole; Humans; Infant, Premature, Diseases; | 2014 |
Fluconazole prophylaxis in neonates.
Topics: Antifungal Agents; Candidiasis, Invasive; Female; Fluconazole; Humans; Infant, Premature, Diseases; | 2015 |
Efficacy and safety of fluconazole prophylaxis in extremely low birth weight infants: multicenter pre-post cohort study.
Topics: Antifungal Agents; Candidiasis, Invasive; Drug Administration Schedule; Drug Resistance, Fungal; Fem | 2016 |
Why prevent invasive Candida infections?
Topics: Antifungal Agents; Candidiasis; Fluconazole; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 2008 |
Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively fluconazole-resistant Candida subspecies.
Topics: Antifungal Agents; Candida; Candidiasis; Chemoprevention; Drug Resistance, Fungal; Female; Fluconazo | 2008 |
Fluconazole prophylaxis decreases the combined outcome of invasive Candida infections or mortality in preterm infants.
Topics: Antifungal Agents; Candida; Candidiasis; Fluconazole; Humans; Infant, Extremely Low Birth Weight; In | 2008 |
Antifungal prophylaxis: identification of preterm neonates at highest risk for invasive fungal infection.
Topics: Antifungal Agents; Candidiasis; Fluconazole; Humans; Infant, Newborn; Infant, Premature, Diseases; I | 2009 |
Efficacy of fluconazole prophylaxis for prevention of invasive fungal infection in extremely low birth weight infants.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Candidiasis; Cholestasis; Female; Fluconazole; Humans; In | 2010 |
Aspergillus fumigatus Meningitis in a Preterm.
Topics: Antifungal Agents; Aspergillosis; Aspergillus fumigatus; Fluconazole; Humans; Infant, Extremely Low | 2010 |
Clinical microbiology of neonatal candidiasis in Hungary.
Topics: Amphotericin B; Candida; Candida albicans; Candida glabrata; Candidiasis; Cesarean Section; Female; | 2010 |
[Recent advances in prevention of sepsis in the preterm neonate].
Topics: Antifungal Agents; Fluconazole; Humans; Infant, Newborn; Infant, Premature, Diseases; Lactoferrin; P | 2010 |
[Invasive candidiasis in neonatal intensive care units].
Topics: Amphotericin B; Antifungal Agents; Candidiasis, Invasive; Catheters; Fluconazole; France; Humans; In | 2011 |
Impact of 'targeted' fluconazole prophylaxis for preterm neonates: efficacy of a highly selective approach?
Topics: Anti-Bacterial Agents; Antifungal Agents; Candidiasis, Invasive; Female; Fluconazole; Humans; Infant | 2012 |
Targeted fluconazole prophylaxis for high-risk very low birth weight infants.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Candidiasis; Cohort Studies; Female; Fluconazole; Gestati | 2012 |
Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Cohort Studies; Creatinine; Fluconazole; Humans; Hyp | 2012 |
Correct choices for correct treatments: key issues in the management of Candida infections in preterm neonates.
Topics: Antifungal Agents; Biofilms; Candida; Candidiasis, Invasive; Echinocandins; Fluconazole; Humans; Inf | 2012 |
[Diagnostic image (143). A neonate with a skin disorder. Congenital cutaneous candidiasis].
Topics: Antifungal Agents; Candidiasis, Cutaneous; Female; Fluconazole; Humans; Infant, Newborn; Infant, Pre | 2003 |
Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit.
Topics: Antifungal Agents; Candida; Candidiasis; Chemoprevention; Drug Resistance, Fungal; Female; Fluconazo | 2005 |
Experience with caspofungin in the treatment of persistent fungemia in neonates.
Topics: Amphotericin B; Antifungal Agents; Candidiasis; Caspofungin; Drug Therapy, Combination; Echinocandin | 2005 |
Successful treatment of Candida glabrata peritonitis with fluconazole plus flucytosine in a premature infant following in vitro fertilization.
Topics: Antifungal Agents; Candida glabrata; Candidiasis; Drug Therapy, Combination; Fertilization in Vitro; | 2005 |
Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study.
Topics: Antifungal Agents; Aspergillosis; Candida; Candidiasis; Fluconazole; Humans; Infant, Newborn; Infant | 2006 |
Fluconazole for the prevention of fungal infections: get ready, get set, caution.
Topics: Antifungal Agents; Candidiasis; Cross Infection; Fluconazole; Humans; Infant, Newborn; Infant, Prema | 2006 |
Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Candidiasis; Fluconazole; Health Care Costs; Humans; Infa | 2006 |
Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis.
Topics: Alkaline Phosphatase; Antibiotic Prophylaxis; Antifungal Agents; Bilirubin; Candidiasis; Case-Contro | 2006 |
Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole, and fluconazole.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Disease Outbreaks; Drug Resistance, Fungal; | 2007 |
Echinocandins--first-choice or first-line therapy for invasive candidiasis?
Topics: Anidulafungin; Antifungal Agents; Candidiasis; Echinocandins; Fluconazole; Fungemia; Humans; Infant, | 2007 |
Antifungal prophylaxis for very low birthweight infants: UK national survey.
Topics: Antifungal Agents; Fluconazole; Health Care Surveys; Humans; Infant, Newborn; Infant, Premature; Inf | 2008 |
Prophylactic fluconazole in preterm neonates.
Topics: Anti-Bacterial Agents; Antifungal Agents; Candidiasis; Fluconazole; Humans; Hygiene; Incidence; Infa | 2007 |
Prophylactic fluconazole in preterm neonates.
Topics: Antifungal Agents; Candidiasis; Fluconazole; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 2007 |
Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure.
Topics: Antifungal Agents; Fluconazole; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2008 |
Candida albicans brain abscesses in a premature infant treated with amphotericin B, flucytosine and fluconazole.
Topics: Amphotericin B; Brain Abscess; Candidiasis; Drug Therapy, Combination; Female; Fluconazole; Flucytos | 1995 |
Renal fungus ball in a premature infant successfully treated with fluconazole.
Topics: Amphotericin B; Candidiasis; Fluconazole; Humans; Infant, Newborn; Infant, Premature; Infant, Premat | 1994 |
Fluconazole monotherapy for candidal meningitis in a premature infant.
Topics: Antifungal Agents; Candidiasis; Fluconazole; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 1996 |
Early onset systemic Candida infection in extremely preterm neonates.
Topics: Antifungal Agents; Candidiasis; Candidiasis, Cutaneous; Female; Fluconazole; Gestational Age; Humans | 1996 |
Nursery outbreak of neonatal fungal arthritis treated with fluconazole.
Topics: Antifungal Agents; Arthritis, Infectious; Candidiasis; Disease Outbreaks; Female; Fluconazole; Human | 1997 |
Pharmacokinetics of oral fluconazole in premature infants.
Topics: Administration, Oral; Antifungal Agents; Candidiasis; Dose-Response Relationship, Drug; Drug Adminis | 1998 |
Persistent candidemia in a premature infant treated with fluconazole.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Fluconazole; Fungemia; Humans; Infant, Newborn; In | 1999 |
Candida arthritis in a premature infant treated successfully with oral fluconazole for six months.
Topics: Administration, Oral; Antifungal Agents; Arthritis, Infectious; Candidiasis; Drug Administration Sch | 2000 |
Fluconazole prophylaxis against fungal infection in preterm infants.
Topics: Antifungal Agents; Candida; Diagnostic Errors; Fluconazole; Humans; Infant, Newborn; Infant, Prematu | 2002 |
Fluconazole prophylaxis against fungal infection in preterm infants.
Topics: Administration, Oral; Antifungal Agents; Candida; Fluconazole; Humans; Infant, Newborn; Infant, Prem | 2002 |
[Candida infections in premature infants weighing less than 1,500 g. Mucocutaneous colonization and incidence of systemic infections].
Topics: Candidiasis, Chronic Mucocutaneous; Cesarean Section; Cross Infection; Cross-Sectional Studies; Drug | 1992 |
Congenital malformations in an infant born to a woman treated with fluconazole.
Topics: Abnormalities, Drug-Induced; Coccidioidomycosis; Congenital Abnormalities; Female; Fluconazole; Huma | 1992 |
Use of fluconazole in the treatment of Candida albicans hydrocephalus shunt infection.
Topics: Candidiasis; Female; Fluconazole; Humans; Hydrocephalus; Infant, Newborn; Infant, Premature, Disease | 1992 |
Fluconazole in neonatal disseminated candidiasis.
Topics: Candidiasis; Fluconazole; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 1991 |